Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
The stock is down 1% to $116.14 after hitting $113.38 earlier in the morning.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts ...
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...
Hosted on MSN22h
Roche reports positive topline outcomes from DMD treatment trialRoche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback